Introduction:
Pharmaron plans to open a new gene production facility to expand its viral vector and DNA manufacturing facilities to more than 8,000 square metres.
Features:
The new facility covers an area of 3,500 sqM for future commercial scale GMP capacity.
This expansion project includes a quadrupling of gene therapy process development and analysis capabilities, which include viral vector, DNA and RNA drug product formulation.
The facility will significantly increase the range of services offered to vaccine, cell and gene therapy customers and enables to continue expand its research team in Liverpool.
The expansion will allow to continue beyond the capacity of the current state-of-the-art development and manufacturing practise facility, which will be fully operational during and after the expansion project.
The new facility is expected to begin in January 2023 and fully be operational in 2024.
Specifications:
Name Pharmaron
Type New Construction
Budget US$189.79 million (£151 million)
Year 2024
